GRCL News and Press, Gracell Biotechnologies Inc. From 11/02/21

SUZHOU, China and PALO ALTO, Calif., Nov. 02, 2021 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) (“Gracell”), a global clinical-stage biopharmaceutical company dedicated to discovering and developing highly efficacious and affordable cell therapies for the tr...

SUZHOU, China and PALO ALTO, Calif., Oct. 15, 2021 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) (“Gracell”), a global clinical-stage biopharmaceutical company dedicated to discovering and developing highly efficacious and affordable cell therapies for the tr...

SUZHOU, China and PALO ALTO, Calif., Aug. 26, 2021 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) (“Gracell”), a global clinical-stage biopharmaceutical company dedicated to discovering and developing highly efficacious and affordable cell therapies for the tr...

Sino Biological completed a $772 million IPO on Shenzhen's ChiNext Exchange. On the first day of trading, the stock closed 68% higher at a market capitalization of $5.2 billion. Beijing InnoCare in-licensed greater China rights to a CD19 targeting mAb from Delaware-based Incyte in a $...

The following slide deck was published by Gracell Biotechnologies Inc. in conjunction with their 2021 Q2 earnings call. For further details see: Gracell Biotechnologies Inc. 2021 Q2 - Results - Earnings Call Presentation

Gracell Biotechnologies, Inc. (GRCL) Q2 2021 Results Earnings Conference Call August 17, 2021, 08:00 AM ET Company Participants William Wei Cao - Founder, Chairman, and Chief Executive Officer Martina Sersch - Chief Medical Officer Kevin Yili Xie - Chief Financial Officer Conference Call Part...

SUZHOU, China and PALO ALTO, Calif., Aug. 17, 2021 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) (“Gracell”), a global clinical-stage biopharmaceutical company dedicated to discovering and developing highly efficacious and affordable cell therapies for the tr...

Gracell Biotechnologies Signs Exclusive License Agreement with FutureGen Biopharm to Develop Engineered Immune Cell Therapies Targeting Claudin 18.2 in Solid Tumors PR Newswire SUZHOU and SHANGHAI, China , and PALO ALTO, Calif. , Aug. 16, 2021 /PRNewswire/ --...

SUZHOU, China and PALO ALTO, Calif., Aug. 03, 2021 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) (“Gracell”), a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of cance...

SUZHOU, China and PALO ALTO, Calif., July 26, 2021 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) (“Gracell”), a global clinical-stage biopharmaceutical company dedicated to discovering and developing highly efficacious and affordable cell therapies for the tr...